Systemic combined with intravitreal methotrexate for relentless placoid chorioretinitis:A case report  

作　　者：Lan Luo Wei-Bin Chen Ming-Wei Zhao Heng Miao 

机构地区：[1]Department of Ophthalmology&Clinical Center of Optometry,Peking University People’s Hospital,Beijing 100044,China [2]Eye Diseases and Optometry Institute,Peking University People's Hospital,Beijing 100044,China [3]College of Optometry,Peking University Health Science Center,Beijing 100191,China [4]Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases,Peking University People's Hospital,Beijing 100044,China

出　　处：《World Journal of Clinical Cases》2022年第35期13115-13121,共7页世界临床病例杂志

基　　金：the National Natural Science Foundation of China,No.81800847;and the Tenth“Academic Star”project of Peking University People's Hospital,No.RS2018-05.

摘　　要：BACKGROUND We describe a case of relentless placoid chorioretinitis(RPC)that progressed despite administration of peribulbar and systemic corticosteroids,and was resolved by systemic combined with intravitreal methotrexate.CASE SUMMARY A 16-year-old male reported painless blurred vision and a temporal scotoma in his right eye for one week.Due to widespread distribution and continuous enlargement,multimodal imaging of the lesions led to the diagnosis of RPC.Lesions in the right eye extended despite peribulbar injection of triamcinolone acetonide,but the progression was immediately terminated by a single dose of intravitreal methotrexate.A new fresh lesion occurred in the contralateral eye despite systemic prednisolone but was resolved by oral methotrexate.CONCLUSION Systemic immunosuppressants should be given upon RPC diagnosis.Intravitreal methotrexate immediately halted progression and may be considered for sightthreatening cases as part of the initial therapy.

关 键 词：IMMUNOSUPPRESSION INTRAVITREAL METHOTREXATE Relentless placoid chorioretinitis SYSTEMIC Case report 

分 类 号：R774.1[医药卫生—眼科]